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Invasive glioblastoma multiforme (GBM) is the most
common malignant primary tumor of the central ner-
vous system with an estimated annual incidence of 3.15
cases per 100,000 in the USA. Current therapies have
been unsuccessful in curing malignant gliomas that are
highly proliferative and infiltrating, containing regions of
necrosis and hypervascularization. Novel therapeutic
approaches are critically needed. A glioma specific
immune response offers a potential anti-tumor benefit
by immune targeted elimination of tumor cells and
memory capability that may prevent future recurrence, a
feature of aggressive GBM. A number of GBM tumor
associated antigens (TAAs) have been studied in precli-
nical and clinical studies. However, most of these TAAs
are HLA motif predicted T cell epitopes derived from
over-expressed proteins. A systematic analysis of the
naturally processed and therefore most clinically rele-
vant MHC class I associated T cell epitopes presented
by glioma cells has never been reported. A number of
tumor associated over expressed glycoproteins have
been identified as biomarkers and have been proposed
as a potential immunotherapeutic target for various can-
cers including GBM. Tumorigenesis involves dysregula-
tion such as over production or high turnover of
proteins that are involved in tumor initiation, progres-
sion, unlimited growth, invasion, immune evasion, ther-
apy resistance and survival. One of the key features of
dysregulation is aberrant glycosylation of glycoproteins
that are involved in these cancer pathways. In this
study, we attempt to identify and characterize T cell epi-
topes presented on the U87 human glioblastoma cells
and select epitopes that are derived from glycosylated
proteins to develop a multi-epitope based therapeutic
vaccine product that induce specific T cell responses
against lethal GBM. Towards this goal, we enriched
GlcNAc expressing glycoproteins using L-PHA lectin
and identified total of 66 glycopeptides derived from 59
different glycoproteins with aberrant GlcNAc glycosyla-
tion from U87 cells via glycoproteomic analysis. We also
used an immunoproteomic approach to investigate
MHC class I presented peptides in tumor cells. Those
selected MHC class I epitiopes were derived from glyco-
sylated proteins that had been identified previously. In
addition, these peptides were able to activate CD8+
T cell responses against glioma cells. Thus the selection
of T cell epitopes derived from aberrantly glycosylated
proteins forms the foundation for the development of a
multi-epitope based therapeutic vaccine that induces
specific T cell responses against lethal GBM.
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